> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Warns Wockhardt’s Morton Grove Unit
- URL: https://www.fdaweb.com/fda-warns-wockhardts-morton-grove-unit/
- Published: 2017-03-02T12:00:00.000Z
- Updated: 2026-09-14T22:09:29.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138109

Wockhardt says its Morton Grove Pharmaceuticals unit received an FDA Warning Letter that indicated that its current portfolio can remain on the market but new approvals will be withheld until issues are resolved. In an online [report](https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=newssearch&cd=45&cad=rja&uact=8&ved=0ahUKEwiIzu2KvrjSAhVCSyYKHT5JCzk4KBCpAggmKAAwBA&url=http%3A%2F%2Fwww.moneycontrol.com%2Fnews%2Fbuzzing-stocks%2Fwockhardt-tanks-7fda%25E2%2580%2599s-warning-letter-to-us-arm%5F8580701.html&usg=AFQjCNEbC6pyFgQKN%5Fsl82-MLJNRtIqAsA&bvm=bv.148747831,d.eWE), India’s *Money Control* Web site says Wockhardt has already been struggling with compliance issues, since two formulation units in India and one bulk drug plant there are under agency import alerts.